LA JOLLA, Calif.--(BUSINESS WIRE)--Traversa Therapeutics, a preclinical-stage biopharmaceutical company developing novel RNA interference (RNAi) technologies, today announced the appointment of William G. Kaelin, Jr., M.D. and Yitzhak Tor, Ph.D. to the company’s scientific advisory board. “We are delighted that both Dr. Kaelin and Dr. Tor have joined our scientific advisory board to guide the advancement of our technologies toward and into the clinic,” said Hans A. Petersen, MBA, President and CEO of Traversa.
